Clinical Trials

Leukemia, Lymphoma, Hematologic Neoplasms

NCT00071045 2026-04-13

Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members

Recruiting

6,000 enrolled

Neoplasms, Hematologic Neoplasms

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT03816345 2026-04-13

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

Phase 1 Recruiting

300 enrolled

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT04439201 2026-04-13

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

40 enrolled 9 charts

Lymphoma, Hematologic Neoplasms

NCT04439292 2026-04-13

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439318 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-04-13

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06303167 2026-04-13

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04959175 2026-04-09

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

320 enrolled

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT00001620 2026-04-08

Screening for Hematology Branch Protocols

Classical hematologyOther hematologic neoplasm

10,000 enrolled

Cytopenia, Anemia, Disease, Hematologic Diseases, Neutropenia, Thrombocytopenia, Hematologic Neoplasms

NCT05470491 2026-04-08

Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

265 enrolled

Acquired Immunodeficiency Syndrome, Hematologic Neoplasms

NCT03854318 2026-03-27

Longitudinal Studies of Patient With FPDMM

Recruiting

1,000 enrolled

Platelet Disorder, Familial, with Associated Myeloid Malignancy, Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Rare Diseases

NCT05436418 2026-03-20

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

260 enrolled

Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06856226 2026-03-09

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Recruiting

88 enrolled

Leukemia, Lymphoma, Hematologic Neoplasms

NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

Phase 1/2 Completed

8 enrolled 20 charts

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

NCT05327023 2026-01-26

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

430 enrolled

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

10 enrolled 15 charts

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT07162038 2026-01-23

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Phase 1 Recruiting

155 enrolled

Hematologic Neoplasms

NCT02315599 2026-01-14

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

500 enrolled

Phase 1/2 Active not recruiting

Hematologic Neoplasms

NCT03983850 2025-12-26

Optimizing PTCy Dose and Timing

105 enrolled

Graft vs Host Disease, Hematologic Neoplasms

NCT02473757 2025-12-01

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

1,000 enrolled

Multiple Myeloma, Leukemia, B-Cell, Hematologic Neoplasms

NCT04439110 2025-11-21

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

38 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439149 2025-11-21

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

24 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439188 2025-11-19

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

35 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439266 2025-11-19

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

5 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439279 2025-11-19

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439344 2025-11-19

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

53 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439123 2025-11-18

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

35 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439175 2025-11-18

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

70 enrolled 9 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439227 2025-10-31

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

35 enrolled

Phase 1 Active not recruiting

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02993146 2025-10-29

Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases

11 enrolled 12 charts

CNSOther hematologic neoplasm

Brain Neoplasms, Hematologic Neoplasms

NCT02862275 2025-10-23

Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer

Phase 1 Active not recruiting

40 enrolled

Neoplasm Metastasis, Hematologic Neoplasms

NCT04439253 2025-09-18

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05600933 2025-09-15

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

DermatologicGastrointestinalOther hematologic neoplasmThoracic

1,200 enrolled

Gastrointestinal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms, Hematologic Neoplasms

NCT04500548 2025-09-10

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Phase 1 Withdrawn

CNSGastrointestinalLymphoidOther hematologic neoplasm

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Lymphoma, Neuroblastoma, Xeroderma Pigmentosum, Central Nervous System Neoplasms, Hematologic Neoplasms

NCT04439136 2025-09-05

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

40 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT00588991 2025-04-02

Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders

Phase 1 Completed

12 enrolled

Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01638533 2025-02-07

Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction

Phase 1 Completed

37 enrolled

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckLymphoidNETOther hematologic neoplasmSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Glioma, Lung Neoplasms, Lymphoma, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Neuroendocrine Tumors, Hematologic Neoplasms

NCT04370834 2025-02-04

Tocilizumab for Patients With Cancer and COVID-19 Disease

Phase 2 Terminated

1 enrolled 10 charts

DermatologicOther hematologic neoplasm

Pneumonia, Respiratory Distress Syndrome, Hematologic Neoplasms

NCT01902173 2025-01-14

Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer

Phase 1/2 Completed

27 enrolled 16 charts

Melanoma, Neoplasm Metastasis, Hematologic Neoplasms

NCT04847050 2024-08-27

A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy

19 enrolled 18 charts

Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT00019097 2024-03-04

Vaccine Therapy in Treating Patients With Multiple Myeloma

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Neoplasms, Hematologic Neoplasms, Genetic Diseases, Inborn, Neoplasms, Plasma Cell

NCT00051311 2021-09-09

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

62 enrolled 15 charts

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439240 2021-06-29

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

52 enrolled 10 charts

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Phase 1 Completed

71 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

47 enrolled 10 charts